ScholarLens Back to search
1996•Current Opinion in RheumatologyRequires access

Disease-modifying antirheumatic drugs, including methotrexate,|gold, sulfasalazine, antimalarials, and D-penicillamine

Philip G. Conaghan, Peter Brooks

Open publisher page 4 citations

Abstract

Conaghan, Philip G. MB, BS, FRACP; Brooks, Peter MD, FRACP, FAFRM, FAFPHM Author Information

About this research paper

What this paper is about

Conaghan, Philip G. MB, BS, FRACP; Brooks, Peter MD, FRACP, FAFRM, FAFPHM Author Information

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Conaghan, Philip G. MB, BS, FRACP; Brooks, Peter MD, FRACP, FAFRM, FAFPHM Author Information

Key concepts: Sulfasalazine, Penicillamine, Medicine, Antirheumatic drugs, Methotrexate, Antirheumatic Agents, Rheumatoid arthritis, Pharmacology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Disease-modifying antirheumatic drugs, including methotrexate,|gold, sulfasalazine, antimalarials, and D-penicillamine — Research Paper | ScholarLens